NCT01961921

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Alnylam Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).

Conditions

• TTR-mediated Amyloidosis

Interventions

Type	Name	Description
DRUG	ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

Timeline

• Start date: 2013-10-01
• Primary completion: 2016-07-01
• Completion: 2016-08-01
• First posted: 2013-10-14
• Last updated: 2024-04-19
• Results posted: 2018-10-30

Locations

9 sites across 7 countries: United States, Brazil, France, Germany, Portugal, Spain, Sweden